Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor-derived CIK cells
- Development stage
- Unknown
- Lead developer
- Papa Giovanni XXIII Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Donor-derived CIK (Cytokine-Induced Killer) cells are an adoptive cellular immunotherapy developed by A.O. Ospedale Papa Giovanni XXIII for the treatment of relapsed hematologic malignancies following haploidentical stem cell transplantation. These cells are an Advanced Therapeutic Medicinal Product (ATMP) consisting of ex vivo-expanded immune effector cells derived from a haploidentical donor's peripheral blood or leukapheresis product. CIK cells are a heterogeneous population, primarily characterized by the co-expression of T cell (CD3) and Natural Killer (NK) cell (CD56) markers. They exert potent, non-MHC-restricted cytolytic activity against tumor cells, particularly leukemia, while maintaining a low potential for inducing graft-versus-host disease (GvHD). The therapy is currently being evaluated in Phase I/II clinical trials (e.g., Haplo-CIK) for conditions including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma, myelofibrosis, and myelodysplastic syndrome (MDS).
- Other names
- unmodified CIKdonor-derived cytokine-induced killer cellshaploidentical donor-derived CIK cells
02
Targets
NKG2D (Natural killer group 2 member D receptor)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on donor-derived CIK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor-derived CIK cells.